The leader in pharma sales, Pfizer is well known thanks to several household name drugs, including Lipitor, Advil, Celebrex, Zithromax and the ever-abundant "little blue pill," Viagra. As the company looks at the looming Lipitor patent cliff, CEO Ian Read has been searching for new methods to keep revenue high, other than new approved drugs. Recently, the company has been considering spinning off portions of the company to create smaller, more profitable arms, a polar opposite of former CEO Jeffrey Kindler's bulk-up strategy of years past. The company's past purchases and mergers have included King Pharmaceuticals, Warner-Lambert, SUGEN and a $68 billion purchase, Wyeth, in 2009.

Wyeth provided Pfizer with an influx of 17 new drugs and vaccines, including Enbrel, Effexor, Prevnar and Pristiq, and Pfizer declared the merger made them "one of the most diversified companies in the global health care industry." And the company continues to move forward as it focuses on hot areas, including Alzheimer's, oncology and vaccines.

The company's legal woes have caused headaches as well. Pfizer has paid over $340 million in settlements for its menopause treatment, Prempro and has 1,200 cases pending for the anti-smoking drug Chantix. Back in 2009, it paid $1.3 billion for illegal marketing fines for the painkiller Bextra, making it the largest fine in United States history.

Pfizer has stayed in the top two on FiercePharma's annual layoffs list for the past three years, thanks in part to the company's 2009 megamerger with Wyeth, and the pressure could be felt for another five years. The company also placed second in the Top 15 R&D Budgets, with $7.4 billion in 2009. But those numbers will continue to slip as Pfizer looks towards development deals instead of in-house research.



Latest Headlines

Latest Headlines

ALSO NOTED: ISTA announces positive data; Proteolix launches Phase II trial; and much more...

> If anyone doubted Andrew Witty's professed faith in emerging markets, those doubts can be put to rest. The incoming GlaxoSmithKline CEO lured Eli Lilly's Abbas Hussein to spearhead a new unit

Counterpoint: An argument for industry-backed research

Management consultant Dr. David A. Shaywitz has joined with Dr. Dennis A. Ausiello, the physician-in-chief of Massachusetts General Hospital and a director at Pfizer, to deliver a rebuttal to a small

Letters show Nigeria OK'd Pfizer trial

Pfizer is back at the negotiating table with the Nigerian state of Kano in an attempt to finally settle claims about a meningitis drug trial the government contends was conducted illegally. The

ALSO NOTED: Novo Nordisk creating 400 NJ jobs; Schering to sell off animal products;

> GlaxoSmithKline is acquiring Cambridge, MA-based Sirtris Pharmaceuticals for $720 million. GSK will pay $22.50 per share for the company.

Zyrtec 'guerilla' flyers spur blog buzz

A new guerilla marketing campaign for over-the-counter Zyrtec proves one thing: If you want attention in the blogosphere, post a few drug ads on telephone poles. They're flyers designed to appear

Ghostwriting fuels foes of FDA rule change

Last week, we reported  on Big Pharma's march on the capital in support of new off-label marketing rules.

Woe is Pfizer, analysts say

Pfizer shares hit a 10-year low yesterday. And who can blame investors who sold, considering the Eeyore tone Wall Street analysts took after the drugmaker announced its

Pharma fighting back in Washington

Call it the backlash against the backlash. In the wake of the recent

Incontinence meds may impair thinking

Commonly used incontinence drugs may cause memory problems in older people, according to a new study funded by the National Institute on Aging. "Our message is to be careful when using these

Neurontin fails bipolar med review

Review the research on epilepsy meds, and what do you find? Neurontin (gabapentin), is no better than placebo for bipolar disorder, according to the Prescribing for Better Outcomes center at the